share_log

RBC Capital Reiterates Outperform on CG Oncology, Maintains $66 Price Target

Benzinga ·  Dec 6 15:48  · Ratings

RBC Capital analyst Gregory Renza reiterates CG Oncology (NASDAQ:CGON) with a Outperform and maintains $66 price target.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment